Alestramustine
![]() | |
Clinical data | |
---|---|
Other names | Alanylestramustine; Estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(L-alaninate); Estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(2β-aminopropanoate); Estradiol 3-(bis(2-chloroethyl)carbamate) 17β-((2S)-2-aminopropanoate) |
Drug class | Chemotherapeutic agent; Estrogen; Estrogen ester |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H36Cl2N2O4 |
Molar mass | 511.48 g·mol−1 |
3D model (JSmol) | |
| |
InChI
|
Alestramustine (INN), also known as estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(L-alaninate), is a cytostatic antineoplastic agent which was never marketed.[1][2] It is the L-alanine ester of estramustine, which is a combination of the nitrogen mustard normustine coupled via a carbamate to the estrogen estradiol.[1][3] Alestramustine acts as a prodrug to estramustine, and also forms estradiol as a byproduct.[1][3] The drug, via its active metabolites, binds to microtubule-associated proteins and β-tubulin and interferes with microtubule function, thereby inhibiting cell division.[1][3] Due to its estrogen moiety, alestramustine is selectively concentrated in estrogen receptor-positive cells such as prostate and breast.[1]
See also[]
- List of hormonal cytostatic antineoplastic agents
- List of estrogen esters § Estradiol esters
References[]
- ^ a b c d e NCI Thesaurus. "Alestramustine". Retrieved 24 June 2016.
- ^ Milne GW (1 July 2000). Ashgate Handbook of Antineoplastic Agents. Wiley. p. 5. ISBN 978-0-566-08382-2.
- ^ a b c Tripathi KD (30 September 2013). Essentials of Medical Pharmacology. JP Medical Ltd. pp. 866–. ISBN 978-93-5025-937-5.
Categories:
- Abandoned drugs
- Antineoplastic drugs
- Chloroethyl compounds
- Estradiol esters
- Estranes
- Hormonal antineoplastic drugs
- Nitrogen mustards
- Organochlorides
- Prodrugs
- Synthetic estrogens
- Antineoplastic and immunomodulating drug stubs
- Genito-urinary system drug stubs
- Steroid stubs